title: [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
abstract: OBJECTIVE
  To analyze the effect of additional chromosome abnormalities on the prognosis and the clinical manifestations of acute promyelocytic leukemia (APL) and the reaction of the patients with additional chromosomes to the treatment of combination of red arsenic sulfide, all trans-retinoic acid (ATRA) and anthracyclin.
  
  
  METHODS
  The clinical data of 158 patients with newly diagnosed APL who were treated with combination of red arsenic sulfide, ATRA, and anthracyclin were analyzed retrospectively.
  
  
  RESULTS
  The frequency of additional chromosome abnormalities in the APL patients was 18.4%, and trisomy 8 and i17q- were the most to be seen. The disseminated intravascular coagulation rate of the patients with additional chromosome abnormality was 62.1%, significantly higher than that of the patients without additional chromosome abnormality (35.6%, P < 0.05). The complete remission rate of the patients with additional chromosome abnormality was 75.9%, not significantly lower than that of those without additional chromosome abnormality (90.7%), and the relapse rate and incidence rate of central nervous system leukemia were 13.8% and 17.2%, both higher, but not significantly, than those of the patients without additional chromosome abnormality (6.2% and 6.2% respectively) (all P > 0.05). There was no significant difference in survival rate between these 2 groups (P = 0.160).
  
  
  CONCLUSIONS
  Additional chromosome abnormality does not significantly influence the prognosis of APL treated with combination of red arsenic sulfide, ATRA, and anthracyclin.
authors.affiliation: Department of Hematology, Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Hao
authors.initials: H
authors.lastname: Jiang
authors.forename: Qian
authors.initials: Q
authors.lastname: Jiang
authors.forename: Li
authors.initials: L
authors.lastname: Bao
authors.forename: Xi-jing
authors.initials: XJ
authors.lastname: Lu
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Lin
authors.forename: Yan-rong
authors.initials: YR
authors.lastname: Liu
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001152:Arsenicals / Q000008:administration & dosage; D002869:Chromosome Aberrations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013440:Sulfides / Q000008:administration & dosage; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D001152:Arsenicals; D013440:Sulfides; C045816:arsenic trisulfide; D014212:Tretinoin